Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations

Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update

(2017) Matteo Molica et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

(2016) W. Wang et al.   BLOOD

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2016) Z Chen et al.   LEUKEMIA

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

(2016) V S Hoffmann et al.   LEUKEMIA

The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study

(2016) Kaan Savasoglu et al.   LEUKEMIA & LYMPHOMA

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

(2015) Alice Fabarius et al.   ANNALS OF HEMATOLOGY

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

(2015) M. W. Deininger et al.   BLOOD

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome

(2014) Marjanu Hikmah Elias et al.   LEUKEMIA RESEARCH

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

(2013) P. Jain et al.   BLOOD

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Detection ofABL1kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea

(2013) Y.-U. Cho et al.   International Journal of Laboratory Hematology

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

(2013) Sureyya Bozkurt et al.   MEDICAL ONCOLOGY

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Genomic Instability in Chronic Myeloid Leukemia: Targets for Therapy?

(2012) N. Muvarak et al.   Current Hematologic Malignancy Reports

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

(2011) Nóra Meggyesi et al.   ACTA HAEMATOLOGICA

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

(2010) Susanne Schnittger et al.   GENES CHROMOSOMES & CANCER

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

(2009) T. D. Kim et al.   HAEMATOLOGICA

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent

(2009) Soo-Hyun Kim et al.   HEMATOLOGICAL ONCOLOGY

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY